CJC-1295 (without DAC) vs GHRP-6
Well Studied vs Well Studied
synergistic Amplifies GH pulse when combined.
Molecular Data
CJC-1295 (without DAC) GHRP-6
Weight 3,367.97 Da 873 Da
Half-life 30 minutes - 2 hours 15-60 minutes
Chain 30 amino acids 6 amino acids
Type GHRH analog Synthetic hexapeptide
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
GHRP-6
01 Potent stimulation of natural growth hormone release
02 Significant increase in appetite (beneficial for bulking/weight gain)
03 Enhanced muscle growth through elevated GH and IGF-1
04 Improved fat metabolism and body composition
05 Cardioprotective effects observed in research
06 Enhanced recovery from exercise and injury
07 Cytoprotective and anti-inflammatory properties
08 Maintains natural GH pulsatile release
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
GHRP-6
100-300 mcg per injection / 2-3 times daily (morning, post-workout optional, before bed)
GH optimization 100 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Appetite/bulking 100-200 mcg Before meals
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
GHRP-6
Intense hunger/increased appetite (most notable side effect)
Water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetes (use with caution)
WADA prohibited for competitive athletes
Research Evidence
CJC-1295 (without DAC) GHRP-6
Status Well Studied Well Studied
References 4 studies 3 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.